03:16 AM EDT, 10/14/2026 (MT Newswires) -- Cellbxhealth (CLBX.L) signed a new statement of work worth $65,000 under a master services agreement, expanding its partnership with an unnamed US-based pharmaceutical company. Under the agreement, the British circulating tumor cell intelligence company will process 100 patient samples through its Parsortix platform for isolation and harvesting of circulating tumor cells for downstream molecular analysis, according to a Wednesday filing.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.